Definition {#S1}
==========

Radiation-induced oral mucositis (RIOM) (Figures [1](#F1){ref-type="fig"}, [4](#F4){ref-type="fig"} and [5](#F5){ref-type="fig"}C) is one of the major ionizing radiation toxicities and normal tissue injuries that result from radiotherapy ([@B1]). RIOM was first termed in 1980 as a side effect of radiotherapy (RT) in cancer patients ([@B2]). RIOM is a normal tissue injury lasting between 7 and 98 days, which starts as an acute inflammation of oral mucosa, tongue, and pharynx after RT exposure ([@B1], [@B3]). This coincides with recruitment of various inflammatory cells and release of inflammatory cytokines, chemotactic mediators, and growth factors. RIOM can progress to an acute life-threatening stage as a result of severe physical obstruction of food and water intake with subsequent weight loss and septic complication due to lost protective epithelial and basement membrane barriers. This leads to limitations of local tumor control due to cancer treatment interruption and alterations in radiation dose fractionation ([@B4]--[@B7]). Studies suggested the stages of progression of RIOM as initial hyperemia and erythema during the preulcer phase, during which there is a release of various pro-inflammatory cytokines from epithelial, vascular, and connective tissue cells at the site of tissue injury. This is followed by the epithelial phase with various degrees of desquamation and basement membrane damage with loss of the protective barrier, which ends with the physical appearance of the ulceration. The postulcerative phase varies depending on the extent of the tissue toxicity. A secondary infection with Gram-negative bacteria or yeast may occur, with microcoagulation of the vasculature that worsens the inflammation by the local ischemia with more necrotic tissue yield. The final stage will be the healing phase and fibrosis ([@B2], [@B8], [@B9]).

![**Pathobiology of oral mucositis (OM) ([@B10])**. Sonis has suggested five stages (phases) of OM injury induced by radiotherapy (RT) and/or chemotherapy (CT): initiation, signaling, amplification, ulceration, and healing. The pathogenesis of each phase is illustrated.](fonc-07-00089-g001){#F1}

RIOM Epidemiology (Incidence, Predictors, and Risk Factors) {#S2}
===========================================================

Radiation-induced oral mucositis occurs in up to 80% of head and neck cancer irradiated patients and reaches up to 100% in patients with altered fractionation head and neck cancer. RIOM of grade 3 and 4 have been recorded in 56% of head and neck cancer patients treated with radiotherapy ([@B1], [@B12]).

Many risk factors have been identified for RIOM. These risk factors include concomitant chemotherapy (CT), bad oral hygiene, below average nutritional stratus, lack of antibiotic use at early stage mucositis, and smoking ([@B13]).

Table [1](#T1){ref-type="table"} shows the significant predictors for the prevalence of severe RIOM and the symptoms of RIOM in a longitudinal study of patients with oral cavity cancer among head and neck cancer outpatients of a radiation department at a major medical center in Taiwan ([@B14]). This study used the Generalized Estimating Equations to analyze the predictive factors of prevalence of severe RIOM and RIOM-related symptoms. They found that the significant predictors for the prevalence of severe RIOM included type of treatment \[RT vs. concomitant chemoradiotherapy (CCRT)\], cumulative radiation dose, smoking, and body mass index (BMI). Patients who received CCRT (Coef. 0.145, *p* \< 0.05), who have a higher cumulative radiation dose (Coef. 0.000, *p* \< 0.01), who are smokers (Coef. 0.090, *p* \< 0.01), and who have lower BMI (Coef. 0.005, *p* \< 0.05) were at high risk to develop severe RIOM. RIOM-related symptoms were also predicted by type of treatment (RT vs. CCRT) (Coef. 1.618, *p* \< 0.05), cumulative radiation dose (Coef. 0.003, *p* \< 0.05), and smoking (Coef. 1.759, *p* \< 0.001). These significant predictors are implemented by radiation oncologists to minimize and/or prevent the RIOM. June Eilers and Rita Million have summarized the patient-linked factors leading to increased risk for RIOM (Table [2](#T2){ref-type="table"}) ([@B15]). They found that very young age, female gender, poor oral health and hygiene, decreased saliva secretion, low BMI, poor renal function with elevated serum creatinine level, smoking, and history of RIOM are risk factors predicting the development of RIOM in head and neck cancer patients ([@B15]).

###### 

**Data analysis for RIOM predictors using IBM SPSS version 21.0 (Armonk, NY, USA) ([@B14])**.

  Variable                        Coef.    SE     z       *p* \> z   95% conf. interval   
  ------------------------------- -------- ------ ------- ---------- -------------------- -------
  **Prevalence of severe RIOM**                                                           
  Treatment type (RT vs. CCRT)    0.145    0.06   5.65    0.017      0.03                 0.26
  Cumulative RT dose (cGy)        0.000    0.03   16.47   0.001      −0.00                0.01
  Smoking (no vs. yes)            0.090    0.03   8.52    0.004      0.03                 0.15
  Body mass index                 −0.005   0.01   4.56    0.033      −0.10                0.00
  Time                            0.417    0.09   23.56   0.001      0.25                 0.59
  Intercept                       −0.277   0.17   2.72    0.099      −0.61                0.05
  **Symptoms of RIOM**                                                                    
  Treatment type (RT vs. CCRT)    1.618    0.49   10.76   0.001      0.65                 2.59
  Cumulative RT dose (cGy)        0.003    0.01   4.03    0.045      −0.01                −0.01
  Smoking (no vs. yes)            1.759    0.41   18.50   0.000      0.96                 2.56
  Body mass index                 −0.002   0.05   0.00    0.973      −0.09                0.09
  Time                            1.338    1.34   2.57    0.109      −0.48                4.77
  Intercept                       6.023    2.77   4.74    0.030      0.60                 11.45

*Significant predictors for RIOM*.

*Significant predictors for the prevalence of severe RIOM (CCRT, cumulative radiation dose, smoking, and low BMI) and the symptoms of RIOM in a longitudinal study of patients with oral cavity cancer among head and neck patients (CCRT, cumulative radiation dose, and smoking)*.

*CCRT, concomitant chemoradiotherapy; RIOM, radiation-induced oral mucositis*.

###### 

**Patient-linked factors leading to increased risk for oral mucositis (OM) ([@B15])**.

  ----------------------------- ---------------------------------------------------------------------------------------------------
  Age                           Increased risk in very young age (high cell turnover rate) and old age (slower healing rate)
  Gender                        Trends to increased risk in females
  Oral health and hygiene       Maintaining good oral hygiene and oral health lowers radiation-induced oral mucositis (RIOM) risk
  Salivary secretory function   Decreased saliva leads to increased RIOM risk
  Genetic factors               Potential for high RIOM risk in certain individuals still to be identified
  Body mass index               Delayed healing and increased breakdown in malnourished individuals
  Renal function                Increased mucotoxicity linked with high serum creatinine level (poor renal function)
  Smoking                       Delays the healing
  Previous cancer treatment     History of mucositis due to previous cancer treatment increases the risk
  ----------------------------- ---------------------------------------------------------------------------------------------------

RIOM Impact and Side Effects {#S3}
============================

Radiation-induced oral mucositis side effects and sequels include oral pain in 69% of patients, dysphagia in 56% of patients, opioid use in 53% of patients, weight loss of 3--7 kg, feeding tube insertion and hospitalization (ICU admission) in 15% of patients, and modification or interruption of treatment in 11--16% of patients ([@B1], [@B12], [@B16]).

In the United States, RIOM may add up to 1,700.00--6,000.00 USD per patient depending on the inflammatory grade of the injury ([@B12]). RIOM treatment adds an economic cost that was estimated to increase up to 17,000.00 USD per patient treated for head and neck cancers ([@B16]).

Radiation-induced oral mucositis injury challenges radiation oncologists from many aspects, such as radiation dose limitations, changes in dose fractionation protocol, and dramatic negative effects on patients' quality of life ([@B1]). The major clinical consequences of RIOM include hospital admission or extended hospitalization for total parenteral nutrition, intravenous (IV) analgesia, and IV antibiotics. Sixty-two percent of patients require hospitalization, and 70% of patients with grade 3--4 oral mucositis (OM) require feeding tube insertion. Reduction or cessation of cancer treatment occurs in 35% of patients due to the developed dose-limiting toxicity ([@B17]).

Pathogenesis and Suggested Mechanistic Pathways {#S4}
===============================================

The pathophysiology of RIOM is not fully understood. Recent studies proposed that the pathogenesis of RIOM is composed of four phases: an initial inflammatory/vascular phase, an epithelial phase, a (pseudomembranous) ulcerative/bacteriological phase, and a healing phase ([@B2], [@B5]).

At the inflammatory phase, the RT-induced tissue injury results in the release of inflammatory cytokines; e.g., interleukin (IL)-1β, prostaglandins (PGs), and tumor necrosis factor-α (TNF-α) from the resident cells such as epithelial, endovascular, and connective tissue. These mediators might increase the damage by increasing the vascular permeability, leading to more infiltration and recruitment of inflammatory cells. Stem cells travel to the site of the tissue injury with other innate immunity components, e.g., MPO-positive leukocytes, macrophages, and neutrophils ([@B18]). On the other hand, there are some anti-inflammatory cytokines, such as IL-10 and IL-11, that work to minimize the injury ([@B18]).

The epithelial phase is initiated within a week by the apoptotic and cytotoxic effects of RT on the proliferating basal cells. This is why the recovery period is dependent on the rate of epithelial turnover, which could be enhanced by growth factors like epidermal growth factor and keratinocyte growth factor (KGF) ([@B19]).

After a week, the epithelial breakdown ends with the beginning of the ulceration. This occurs, when epithelial loss leads to disrupted basement membrane, formation of ulcer pseudomembrane, and inflammatory exudate. The ulceration stage is very painful, since the protective barrier that covers the nerve endings at the lamina propria is lost ([@B19]). The resulting microcoagulation and neutropenic state facilitate the Gram-negative bacteria and yeast colonization with the production of secondary infection. Bacterial exotoxins aggravate the inflammatory reaction by inducing mononuclear burst with the release of more IL-1β, TNF-α, and nitric oxide ([@B8], [@B9], [@B16], [@B20]).

Signaling pathways suggested to be involved in RIOM pathobiology include nitrogen metabolism, Toll-like receptor signaling, nuclear factor-κB (NF-κB) signaling, B-cell receptor signaling, P13K/AKT signaling, cell cycle: G2/M DNA damage checkpoint receptor, p38 mitogen-activated protein kinase (MAPK) signaling, Wnt/B-catenin signaling, glutamate receptor signaling, integrin signaling, vascular endothelial growth factor signaling, IL-6 signaling, death receptor signaling, and SAPK/JNK signaling (Table [3](#T3){ref-type="table"}) ([@B10], [@B19]).

###### 

**Signaling pathways involved in the development of mucositis ([@B10])**.

  -------------------------------------------------
  B-cells receptor signaling
  Cell cycle: G2/M DNA damage checkpoint receptor
  Death receptor signaling
  Glutamate receptor signaling
  Interleukin-6 signaling
  Integrin signaling
  Nuclear factor-κB signaling
  Nitrogen metabolism
  PI3K/AKT signaling
  P38 mitogen-activated protein kinase signaling
  SAPK/JNK signaling
  Toll-like receptor signaling
  Vascular endothelial growth factor signaling
  Wnt/B-catenin signaling
  -------------------------------------------------

In 2004, Sonis suggested five stages (phases) of OM injury induced by radiotherapy (RT) and/or CT: initiation, signaling, amplification, ulceration, and healing (Figure [1](#F1){ref-type="fig"}) ([@B16]).

In 2009, Redding summarized Sonis' RIOM pathobiology phases (Figure [2](#F2){ref-type="fig"}). The initiation phase with RT and/or CT injury results in direct and lethal DNA damage with the release of reactive oxygen species (ROS) from epithelial and vascular endothelial cells, fibroblasts, and tissue macrophages. This is followed by amplification of this signal ([@B11]). During the primary damage response, the DNA damage and ROS act through three major pathways: (1) fibronectin breakdown, which stimulates the macrophages leading to activation of the matrix metalloproteinases (MMPs), (2) nuclear factor-κB (NF-κB) activation, which stimulates the gene expression and the release of pro-inflammatory cytokines, e.g., TNF-α, IL-1β, and IL-6, and (3) ceramide pathway through sphingomyelinase and ceramide synthase. The end result will be more tissue injury and stimulated apoptosis ([@B11]). During the signal amplification phase, there is restimulation of tissue damage and apoptosis by the major pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), NF-κB-mediated gene expression, and ceramide and caspase pathways. The basement membrane protective barrier is lost during the ulceration phase. This leads to Gram-negative and yeast secondary infection potential, which adds more pro-inflammatory reactions and complicates the already existing inflammation. The healing phase starts by matrix signaling to basal epithelial cells to migrate, proliferate, and differentiate ([@B11]). Signal amplification during RIOM or CT-induced OM is a main step in this treatment-induced injury, according to Sonis et al. ([@B17]). RT and/or CT activate the transcription factor NF-κB in epithelial, endothelial, and mesenchymal cells and macrophages, resulting in upregulation of genes and production of pro-inflammatory cytokines: tumor necrosis factor-α (TNF-α) and IL-1β, which amplify the primary signal and activate NF-κB. This leads to transcription of genes responsible for MAPK, cyclooxegenase-2 (COX-2), and tyrosine kinase signaling molecules. These signaling pathways activate MMPs 1 and 3 in the epithelial and lamina propria cells, which collectively cause tissue injury ([@B10]) (Figure [3](#F3){ref-type="fig"}).

![**Redding's summary of RT and/or chemotherapy (CT)-induced oral mucositis pathobiology ([@B11])**. Redding has summarized the pathobiology phases of radiation-induced oral mucositis induced by RT and/or CT. In brief, initiation phase with RT and/or CT results in direct and lethal DNA damage, which leads to release of reactive oxygen species (ROS) from epithelial, vascular endothelial, fibroblasts, and tissue macrophages with cycles of amplifications. Within such primary damage response, the DNA damage and ROS lead to three major steps: (1) fibronectin breakdown that activates macrophages ending with stimulation of matrix metalloproteinase; (2) nuclear factor-κB (NF-κB) activation that stimulates the gene expression and release of pro-inflammatory cytokines, e.g., TNF-α, interleukin (IL)-1β, and IL-6; and (3) ceramide pathway through sphingomyelinase and ceramide synthase. The result will be more tissue injury and stimulated apoptosis. During the signal amplification phase, there is restimulation of tissue damage and apoptosis by the major pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), NF-κB-mediated gene expression, and ceramide and caspase pathways. During the ulceration and loss of the protective barrier, secondary infection adds more pro-inflammatory reactions and complicates the already existing inflammation before the healing phase starts by matrix signaling to basal epithelial cells to migrate, proliferate, and differentiate. Republished with the permission of Dr. Redding. **(A)** Initial phase, **(B)** primary damage phase, **(C)** signal amplification phase, and **(D)** ulcerative phase.](fonc-07-00089-g002){#F2}

![**Signal amplification during OM induced by RT and/or CT ([@B10])**. Signal amplification during RT- and/or CT-induced OM is mediated by activation of NF-κB that is reactivated by IL-1β. NF-κB induces the expression of genes responsible for the MAPK, COX-2, and tyrosine kinase pathways to finally activate the MMP1 and MMP3 signaling at the injured tissue cells. TNF-α, tumor necrosis factor-α; IL-1β, interleukin-1β; NF-κB, nuclear factor-κB; MAPK, mitogen-activated protein kinase; COX-2, cyclooxegenase-2; MMP1, matrix metalloproteinase 1; MMP3, matrix metalloproteinase 3; OM, oral mucositis; CT, chemotherapy. Republished with the permission of Dr. Sonis.](fonc-07-00089-g003){#F3}

RIOM Grading and Scoring Scales {#S5}
===============================

There has been more than one grading scale for RIOM. Table [4](#T4){ref-type="table"} shows the comparison of different RIOM scoring scales ([@B14], [@B21]--[@B23]).

###### 

**Comparison of OM scoring scales ([@B14], [@B21]--[@B23])**.

  Grade            0                   1                        2                                                      3                                                                      4
  ---------------- ------------------- ------------------------ ------------------------------------------------------ ---------------------------------------------------------------------- -----------------------------------------------------------
  WHO              None                Soreness ± erythema      Erythema, ulcers, and patient can swallow solid food   Ulcers with extensive erythema and patient cannot swallow solid food   mucositis to the extent that alimentation is not possible
  RTOG             None                Erythema of the mucosa   Patchy reaction \<1.5 cm, non-contiguous               Confluent reaction \>1.5 cm, contiguous                                Necrosis or deep ulceration, ±bleeding
  WCCNR            Lesions: none       Lesions: 1--4            Lesions: \>4                                           Lesions: coalescing                                                    N/A
  Color: pink      Color: slight red   Color: moderate red      Color: very red                                                                                                               
  Bleeding: none   Bleeding: N/A       Bleeding: spontaneous    Bleeding: spontaneous                                                                                                         

*WHO, World Health Organization; RTOG, Radiation Therapy Oncology Group; WCCNR, Western Consortium for Cancer Nursing Research; OM, oral mucositis*.

World Health Organization Oral Toxicity Scale measures the anatomical, symptomatic, and functional elements of OM (Figure [4](#F4){ref-type="fig"}). The Radiation Therapy Oncology Group (RTOG) determined the acute radiation morbidity scoring criteria for mucous membranes. Finally, the Western Consortium for Cancer Nursing Research describes only the anatomical changes associated with OM ([@B24]).

![**World Health Organization's Oral Toxicity Scale**. Republished with the permission of Dr. Patrick Stiff, Loyola University Medical Center, Maywood, IL, USA.](fonc-07-00089-g004){#F4}

Radiation Therapy Oncology Group developed the Acute Radiation Morbidity Scoring Criteria for the evaluation of RT effects (another criterion was generated for late effects of RT) ([@B25]). The National Cancer Institute (NCI) Common Toxicity Criteria (NCI-CTC) scores CT-related side effects. The RTOG was gathered with the NCI-CTC to produce version 2.0, which has been used in all NCI clinical trials since March 1998 (Table [5](#T5){ref-type="table"}) ([@B2], [@B25], [@B26]).

###### 

**Toxicity grading of oral mucositis (OM) according to World Health Organization (WHO) and National Cancer Institute Common Toxicity Criteria (NCI-CTC) criteria ([@B2])[^a^](#tfn1){ref-type="table-fn"}**.

  Side effect                                                                                          Grade 0 (none)   Grade 1 (mild)                                                          Grade 2 (moderate)                                                                            Grade 3 (severe)                                                                                                                 Grade 4 (life threatening)
  ---------------------------------------------------------------------------------------------------- ---------------- ----------------------------------------------------------------------- --------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------
  WHO oral mucositis (stomatitis)                                                                      None             Oral soreness, erythema                                                 Oral erythema, ulcers, can eat solids                                                         Oral ulcers, requires liquid diet only                                                                                           Oral alimentation not possible
                                                                                                                                                                                                                                                                                                                                                                                                                               
  NCI-CTC chemotherapy-induced stomatitis/pharyngitis (oral/pharyngeal mucositis)                      None             Painless ulcers, erythema, or mild soreness in the absence of lesions   Painful erythema, edema, or ulcers, but can eat or swallow                                    Painful erythema, edema, or ulcers requiring intravenous hydration                                                               Severe ulceration or requires parenteral or enteral nutritional support or prophylactic intubation
                                                                                                                                                                                                                                                                                                                                                                                                                               
  NCI-CTC mucositis due to radiation                                                                   None             Erythema of the mucosa                                                  Patchy pseudomembranous reaction (patches generally ≤1.5 cm in diameter and non-contiguous)   Confluent pseudomembranous reaction (contiguous patches generally \>1.5 cm in diameter)                                          Necrosis or deep ulceration; may include bleeding not induced by minor trauma or abrasion
                                                                                                                                                                                                                                                                                                                                                                                                                               
  NCI-CTC stomatitis/pharyngitis (oral/pharyngeal mucositis) for bone marrow transplantation studies   None             Painless ulcers, erythema, or mild soreness in the absence of lesions   Painful erythema, edema, or ulcers, but can swallow                                           Painful erythema, edema, or ulcers preventing swallowing or requiring hydration or parenteral (or enteral) nutritional support   Severe ulceration requiring prophylactic intubation or resulting in documented aspiration pneumonia

*^a^Republished with the permission of Dr. Christoph C. Zielinski*.

The OM Index (OMI) scores the severity of OM by the erythema, ulceration, atrophy, and edema (a scale of 0--3 was designated for each element: 0 = none and 3 = severe). The OMI is considered internally consistent with high test--retest and interscorer reliability, and it shows solid validity ([@B27]).

The OM Assessment Scale (OMAS) is a highly reproducible scoring scale for RIOM, responsive over time, and accurate in detecting OM-associated elements ([@B25]). OMAS records the objective assessment of OM depending on the scoring of the presence and size of the ulceration or pseudomembrane (score 0--3: 0 = no lesion; 1 = lesion of \<1 cm^2^; 2 = lesion of 1--3 cm^2^; 3 = lesion \>3 cm^2^) and erythema (score 0--2: 0 = none; 1 = not severe; 2 = severe) on the upper and lower lips, right and left cheeks, right and left ventral and lateral tongue, floor of the mouth, soft palate, and hard palate ([@B23], [@B28]).

All these scoring scales are validated and are required in assessing RIOM and the therapeutic benefits of any new treatment of RIOM.

Diagnosis of RIOM {#S6}
=================

Radiation-induced oral mucositis can develop within or after 2 weeks from the beginning of RT. Oral assessment guide could be a useful tool for detection of early OM (Table [6](#T6){ref-type="table"}) ([@B20]). Apart from the early clinical signs and symptoms, CBC with differential is considered the baseline to help radiation oncologists to determine the most susceptible time for developing OM or oral infection. Radiation oncologists can start the RT provided that there is no evidence of any periodontal disease. If at any point RIOM develops, oral lesion culture and antimicrobial therapy are recommended as soon as possible ([@B29]). Since renal diseases are considered contributing factors for OM ([@B15]), chemistry levels should be regularly monitored by the treating physician ([@B29]).

###### 

**Oral assessment guide ([@B30])**.

  Item/grade            1                       2                               3
  --------------------- ----------------------- ------------------------------- ------------------------------------------
  Voice                 Normal                  Deeper or raspy                 Difficulty talking
  Swallow               Normal                  Some pain                       Unable to swallow
  Lips                  Smooth pink and moist   Dry or cracked                  Ulcerated or bleeding
  Tongue                Pink and moist          Coated and shiny ± red          Blistered or cracked
  Saliva                Watery                  Thick                           Absent
  Mucus membrane        Pink and moist          Red and coated without ulcers   Ulcers
  Gingiva               Pink and firm           Edematous ± redness             Spontaneous or pressure-induced bleeding
  Teeth/denture areas   Clean, no debris        Plaque and localized debris     Generalized plaque or debris

Differential Diagnosis of RIOM {#S7}
==============================

Because similar conditions can coexist in immunocompromised patients including cancer patients receiving RT and/or CT, differential diagnosis for RIOM is critical. Table [7](#T7){ref-type="table"} shows possible similar conditions (Figure [5](#F5){ref-type="fig"}) ([@B20], [@B31]).

###### 

**Differential diagnosis of RIOM ([@B20], [@B31])**.

  Disease/injury                 Cause                                               Clinical presentation/lab findings                                                      Severity                                          Treatment options
  ------------------------------ --------------------------------------------------- --------------------------------------------------------------------------------------- ------------------------------------------------- -------------------------------------------------------------
  Oral mucositis                 Chemotherapy and radiation therapy                  Diffuse redness, ulcerations, and pain, particularly in areas where teeth abut tissue   Varies; in BMT setting up to 98% have grade 3/4   Palliative rinses, narcotics, palifermin in the BMT setting
  Aphthous stomatitis            Etiology not identified                             Single painful ulcer                                                                    Localized, but painful; maximum grade 2           Topical
  Herpetic mucositis             HSV1                                                Usually several spots; ulcerative                                                       Usually grade 1--2                                Acyclovir, valacyclovir, foscarnet
  Oral thrush                    Candida                                             Varies from painless to mild soreness; whitish plaques                                  Usually grade 0--1                                Nystatin rinses; fluconazole and other azoles
  Denture/oral trauma            Dentures                                            Common in elderly patients with loose-fitting dentures                                  Can limit calories                                Repair, removal of dentures
  Gangrenous stomatitis          Bacterial infections                                Necrotic pseudomembranes                                                                Rare, can be severe                               Antibacterials that treat oral aerobes and anaerobes
  Acute necrotizing stomatitis   Bacterial infections in immune-deficient patients   Pain, fever, necrotic, bloody ulcers                                                    Grade 3/4                                         Control of infection

*BMT, bone marrow transplantation; RIOM, radiation-induced oral mucositis; HSV1, herpes simplex virus type 1*.

![**Differential diagnosis of radiation-induced oral mucositis**. Republished with the permission of Dr. Patrick Stiff, Loyola University Medical Center, Maywood, IL, USA. **(A)** Local, denture-related lesion, **(B)** aphthous ulcer, **(C)** oral mucositis, and **(D)** oral thrush.](fonc-07-00089-g005){#F5}

Prognosis of RIOM {#S8}
=================

The general long-term prognosis is reasonably good since most lesions resolve within 2--4 weeks after stopping the RT or CT. Although RIOM is considered a self-limited injury in some patients, it could be a lethal injury in moderately to severely ill patients, which could lead to ICU admission with obligatory cessation of RT. Patient losses are a common event under these circumstances ([@B32]).

Prevention of RIOM {#S9}
==================

Maintaining good oral care is the main preventive measure for RIOM to minimize the risk for candidiasis or secondary bacterial infection, especially in hyperfractionated radiotherapy, combined CCRT regimens, or RT combined with a targeted agent due to increased mucositis severity ([@B3]). We will summarize the most recent agents and measures to prevent RIOM.

1.  Good oral hygiene

    Good oral hygiene has been found to be one of the most effective ways to lower the risk of RIOM and minimize its progression. Pre-existing oral pathology, e.g., dental caries, periodontal lesions, pulpal disease, and oral xerostomia, has been linked with increased bacteria colonization and severe RIOM. It is recommended to do early oral examination before starting any mucosal toxic therapy for cancer patients. To help minimize the oral side effects of antineoplastic therapy, it is recommended to eliminate any oral pathology before the beginning of RT. This may be accomplished by performing early histological, cytological, microbiologic, and serologic examinations ([@B2]). The Multinational Association of Supportive Care in Cancer (MASCC) and the International Society of Oral Oncology (ISOO) guidelines recommend the use of a standardized oral care protocol, e.g. brushing with a soft toothbrush, flossing and the use of non-medicated rinses (saline or sodium bicarbonate rinses) (Table [9](#T9){ref-type="table"}) ([@B33]--[@B36]). The good oral care can be summarized as follows:

    1.  Rinsing with a non-irritating solution, e.g., saline to increase the quality of saliva.

    2.  Daily ultrasoft tooth brushing with fluoride toothpaste.

    3.  Scaling and cleaning.

    4.  Very soft diet with low sugar and non-acidic food and drinks (Table [8](#T8){ref-type="table"}).

    5.  Flossing is not recommended due to low platelet count.

    6.  Minimize denture use.

    7.  No smoking or alcohol.

    8.  Other preventive procedures include minimizing the microbial load (will be discussed more in the treatment section) and educating the patient on good oral hygiene, which is mandatory.

2.  Cryotherapy has been recommended for CT-induced OM, but no proven role in RIOM due to insufficient evidence ([@B33]).

3.  Keratinocyte growth factor is an epithelial mitogen that reduces the levels of ROS by activating nuclear factor (erythroid-derived 2)-like 2 and had been used in RIOM with promising results ([@B37]--[@B53]). It appears to be one of the promising treatment and prevention options for RIOM that has been investigated in clinical trials ([@B39], [@B43]). Palifermin (IV recombinant human KGF-1) had been approved by the US-FDA for minimizing OM in hematologic malignancies' patients who receive myelotoxic therapies and require hematopoietic cell support after its reliable results in alleviating WHO grade 3 and 4 OM in these patients. Palifermin is delivered IV 3 days before of CT/RT and for 3 days after CT. Palifermin should be avoided on the same day of CT/RT ([@B33]).

4.  Amifostine is a free-radical scavenger, antioxidant, and cytoprotective agent that was administered subcutaneously (SC) and IV in many clinical trials for RIOM. Amifostine is conventionally given IV before RT or CT. It is approved by the US-FDA to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. In addition, it was approved for by the US-FDA to reduce the incidence of moderate to severe xerostomia in patients undergoing postoperative RT for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands ([@B33], [@B54]--[@B62]). Although there was a reduction in the pro-inflammatory cytokine production, its side effects, e.g., hypotension and nausea, were recorded, particularly with IV route. Nevertheless, SC injection 60 min before RT in head and neck cancer patients showed marked reduction of these side effects, unfortunately, with reduced efficacy and patient compliance. Only cutaneous toxicity was noted in SC route of amifostine delivery ([@B54], [@B55]). For moderate to severe RT-induced xerostomia in head and neck cancer patients, the recommended dose of amifostine is 200 mg/m^2^ once daily over 3 min IV, starting 15--30 min before standard fraction RT (1.8--2.0 Gy). Blood pressure should be monitored before, during, and after the IV infusion. Oral 5-HT3 receptor antagonists with/without other antiemetics are recommended before amifostine therapy ([@B63]--[@B65]).

5.  Radiation shields (intraoral devices), midline mucosa-sparing blocks, 3-D and RT field design, intensity-modulated radiation therapy (IMRT), and removal of separable prosthetics are shown in preclinical studies to reduce the radiation scatter and the RIOM injury ([@B66]--[@B69]).

6.  Low-energy helium--neon laser applied before RT showed significant reduction in the duration and the severity of RIOM in head and neck cancer patients ([@B70]). MASCC/ISOO guidelines suggest the use of low-level laser therapy in CT-induced OM at centers that can provide the necessary technology and training ([@B33]).

###### 

**Diet recommended for RIOM patients ([@B20])**.

  Typically accessed diet                           Things to avoid                            Habits to avoid
  ------------------------------------------------- ------------------------------------------ -----------------
  Liquids                                           Rough food (potato chips, crisps, toast)   Smoking
  Purees                                            Spices                                     Alcohol
  Ice                                               Salt                                       
  Custards                                          Acidic fruit (grapefruit, lemon, orange)   
  Non-acidic fruits (banana, mango, melon, peach)                                              
  Soft cheeses                                                                                 
  Eggs                                                                                         

###### 

**Multinational Association for Supportive Care in Cancer/International Society for Oral Oncology (MASCC/ISOO) Clinical Practice Guidelines for oral mucositis ([@B3])**.

  Intervention/mode of administration                                                                                                                                    Purpose            Cancer treatment                                                                                                                                            Level of evidence
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  **Recommendations in favor of an intervention (strong evidence supports effectiveness in the treatment setting listed)**                                                                                                                                                                                                                              
                                                                                                                                                                                                                                                                                                                                                        
  Oral cryotherapy for 30 min                                                                                                                                            Prevention of OM   Patients receiving bolus 5-fluorouracil chemotherapy                                                                                                        Level II
                                                                                                                                                                                                                                                                                                                                                        
  Recombinant human keratinocyte growth factor-1 (palifermin) at a dose of 60 µg/kg per day for 3 days prior to conditioning treatment and for 3 days after transplant   Prevention of OM   Patients receiving high-dose chemotherapy and TBI, followed by autologous stem cell transplantation, for a hematological malignancy                         Level II
                                                                                                                                                                                                                                                                                                                                                        
  Low-level laser therapy (wavelength at 650 nm, power of 40 mW, and each square centimeter treated with the required time to a tissue energy dose of 2 J/cm^2^)         Prevention of OM   Patients receiving HSCT conditioned with high-dose chemotherapy, with or without TBI                                                                        Level II
                                                                                                                                                                                                                                                                                                                                                        
  Patient-controlled analgesia with morphine                                                                                                                             Pain reduction     Patients undergoing HSCT                                                                                                                                    Level II
                                                                                                                                                                                                                                                                                                                                                        
  Benzydamine mouthwash                                                                                                                                                  Prevention of OM   Patients with HNC receiving moderate dose radiation therapy (up to 50 Gy), without concomitant chemotherapy                                                 Level II
                                                                                                                                                                                                                                                                                                                                                        
  **Suggestions in favor of an intervention (weaker evidence supports effectiveness in the treatment setting listed)**                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                        
  Oral care protocols                                                                                                                                                    Prevention of OM   All age groups and across all cancer treatment modalities                                                                                                   Level III
                                                                                                                                                                                                                                                                                                                                                        
  Oral cryotherapy                                                                                                                                                       Prevention of OM   Patients receiving high-dose melphalan, with or without TBI, as conditioning for HSCT                                                                       Level III
                                                                                                                                                                                                                                                                                                                                                        
  Low-level laser therapy (wavelength around 632.8 nm)                                                                                                                   Prevention of OM   Patients undergoing radiotherapy, without concomitant chemotherapy, for HNC                                                                                 Level III
                                                                                                                                                                                                                                                                                                                                                        
  Transdermal fentanyl                                                                                                                                                   Pain reduction     Patients receiving conventional or high-dose chemotherapy, with or without TBI                                                                              Level III
                                                                                                                                                                                                                                                                                                                                                        
  2% morphine mouthwash                                                                                                                                                  Pain reduction     Patients receiving chemoradiation for HNC                                                                                                                   Level III
                                                                                                                                                                                                                                                                                                                                                        
  0.5% doxepin mouthwash                                                                                                                                                 Pain reduction     All patients with OM-induced pain                                                                                                                           Level IV
                                                                                                                                                                                                                                                                                                                                                        
  Systemic zinc supplements administered orally                                                                                                                          Prevention of OM   HNC patients receiving radiation therapy or chemoradiation                                                                                                  Level III
                                                                                                                                                                                                                                                                                                                                                        
  **Recommendations against interventions (strong evidence indicates lack of effectiveness in the treatment setting listed)**                                                                                                                                                                                                                           
                                                                                                                                                                                                                                                                                                                                                        
  PTA (polymyxin, tobramycin, amphotericin B) and BCoG (bacitracin, clotrimazole, gentamicin)                                                                            Prevention of OM   Patients receiving radiation therapy for HNC                                                                                                                Level II
                                                                                                                                                                                                                                                                                                                                                        
  Iseganan antimicrobial mouthwash                                                                                                                                       Prevention of OM   Patients receiving high-dose chemotherapy, with or without TBI, for HSCT or in patients receiving radiation therapy or concomitant chemoradiation for HNC   Level II
                                                                                                                                                                                                                                                                                                                                                        
  Iseganan antimicrobial mouthwash                                                                                                                                       Prevention of OM   Patients receiving high-dose chemotherapy, with or without TBI, for HSCT or in patients receiving radiation therapy or concomitant chemoradiation for HNC   Level II
                                                                                                                                                                                                                                                                                                                                                        
  Sucralfate mouthwash                                                                                                                                                   Prevention of OM   Patients receiving chemotherapy for cancer (I), or inpatients receiving radiation therapy (I) or concomitant chemoradiation (II) for HNC                    Level I, II
                                                                                                                                                                                                                                                                                                                                                        
  Sucralfate mouthwash                                                                                                                                                   Treatment of OM    Patients receiving chemotherapy for cancer (I), or in patients receiving radiation therapy (II) for HNC                                                     Level I, II
                                                                                                                                                                                                                                                                                                                                                        
  Intravenous glutamine                                                                                                                                                  Prevention of OM   Patients receiving high-dose chemotherapy, with or without TBI, for HSCT                                                                                    Level II
                                                                                                                                                                                                                                                                                                                                                        
  **Suggestions against interventions (weaker evidence indicates lack of effectiveness in the treatment setting listed)**                                                                                                                                                                                                                               
                                                                                                                                                                                                                                                                                                                                                        
  Chlorhexidine mouthwash                                                                                                                                                Prevention of OM   Patients receiving radiation therapy for HNC                                                                                                                Level III
                                                                                                                                                                                                                                                                                                                                                        
  Granulocyte-macrophage colony-stimulating factor mouthwash                                                                                                             Prevention of OM   Patients receiving high-dose chemotherapy, for autologous or allogeneic HSCT                                                                                Level II
                                                                                                                                                                                                                                                                                                                                                        
  Misoprostol mouthwash                                                                                                                                                  Prevention of OM   Patients receiving radiation therapy for HNC                                                                                                                Level III
                                                                                                                                                                                                                                                                                                                                                        
  Systemic pentoxifylline, administered orally                                                                                                                           Prevention of OM   Patients undergoing HSCT                                                                                                                                    Level III
                                                                                                                                                                                                                                                                                                                                                        
  Systemic pilocarpine, administered orally                                                                                                                              Prevention of OM   Patients receiving radiation therapy for head and neck cancer (III), or patients receiving high-dose chemotherapy, with or without TBI, for HSCT (II)       Level II and III

*OM, oral mucositis; HSCT, hematopoietic stem cell transplantation; TBI, total body irradiation; HNC, head and neck cancer*.

*Criteria for each level of evidence ([@B34])*.

*Level I: evidence obtained from meta-analysis of multiple, well-designed, controlled studies; randomized trials with low false-positive and false-negative errors (high power)*.

*Level II: evidence obtained from at least one well-designed experimental study; randomized trials with high false-positive and/or false-negative errors (low power)*.

*Level III: evidence obtained from well-designed, quasi-experimental studies such as non-randomized, controlled single-group, pretest--posttest comparison, cohort, time, or matched case--control series*.

*Level IV: evidence obtained from well-designed, non-experimental studies, such as comparative and correlational descriptive and case studies*.

*Level V: evidence obtained from case reports and clinical examples*.

Symptomatic Treatment of RIOM {#S10}
=============================

No single agent has been approved by the US-FDA for the treatment of RIOM. Symptoms reduction and complications prevention of RIOM, including nutritional support, pain control, prophylaxis, and/or treatment of secondary infections, are considered the main cornerstone in the management of RIOM ([@B34]--[@B36]). Agents that were investigated and/or applied in RIOM treatment are discussed in the context of recently updated evidence-based preclinical and clinical studies.

I.  Locally applied agents

    1.  Glycyrrhetinic acid/povidone/sodium hyaluronate gel has mechanical action implemented in the relief of pain in RIOM. It adheres to the mucosal surface of the mouth, soothing oral lesions. Nevertheless, the preclinical studies are controversial, and only one clinical trial on unknown results was conducted to date ([@B71]).

    2.  [l]{.smallcaps}-Glutamine is a non-essential amino acid that counteracts RT-induced metabolic deficiencies ([@B72]). Locally applied [l]{.smallcaps}-glutamine reduced the RIOM in a randomized clinical trial ([@B73]). Glutamine powder for oral suspension was approved by the US-FDA for topical application in management of CT-induced OM, mainly IOMyet ([@B74]).

    3.  Manganese superoxide dismutase is a detoxifying agent that removes ROS. It was shown to have radioprotective effects against RT-induced colitis, esophagitis, hepatic cells apoptosis, and intestinal and eye injury ([@B75]--[@B98]). Phase I dose escalation study of GC4419 (manganese-containing macrocyclic ligand complex similar to naturally occurring superoxide dismutase enzymes) in combination with CT/RT for squamous cell cancer of the head and neck has just been completed waiting for results release (NCT01921426).

    4.  Local anesthetics, e.g., diphenhydramine, viscous xylocaine, lidocaine, and dyclonine hydrochloride, are used for short-term relief of pain associated with RIOM, despite the fact that they can interfere with the taste sensation leading to hypoalimentation ([@B99], [@B100]). Swishing and gargling the anesthetic viscous gel containing 2% lidocaine and holding 5 mL of it in mouth for 1 min then spitting it out before meals have been shown to be helpful for better alimentation ([@B101]). One clinical trial showed dyclonine hydrochloride to have a superior effect among all other agents without significant difference recorded ([@B102]). The most effective anesthetic agent is still to be determined. Benzocaine gel is another locally applied bioadhesive agent containing benzyl alcohol (10%) and is used to relieve pain and facilitate eating and drinking in mild and moderate RIOM ([@B103]). Benzocaine-containing lozenges are diluted to alleviate the pain sensation and mechanical sensitivity in mild to moderate OM ([@B104], [@B105]). The "magic mouthwash" (lidocaine, diphenhydramine, magnesium aluminum hydroxide) and morphine mouth washes are preferable and have been reported by patients to be effective in alleviating pain in RIOM ([@B106]--[@B108]).

    5.  The application of corticosteroids mouthwashes has shown promising results. The limited availability of a large-scale data is a gap that should be bridged through relevant clinical studies ([@B109]).

    6.  Allopurinol and uridine were shown to be effective in reducing 5-fluorouracil oral toxicity in preclinical studies ([@B110]--[@B114]). Despite these results, they were ineffective approaches in randomized clinical trials as a therapy to reduce the treatment-related oral toxicity ([@B115], [@B116]).

    7.  Chlorhexidine is a bisguanidine exhibiting broad-spectrum antibacterial and antimycotic activities. The clinical trials done with chlorhexidine concluded that it cannot be recommended for the prophylaxis or the treatment of RIOM ([@B117]--[@B120]). Alcohol-containing chlorhexidine mouth rinse should be avoided during clinical oral ulceration. Therefore, the MASCC/ISOO guidelines recommend against the use of chlorhexidine mouth rinse for prevention or treatment OM ([@B33]).

    8.  Artificial saliva spray is an over-the-counter agent frequently used to alleviate mucosal dryness in mild cases of RIOM ([@B121]).

    9.  Chamomile has anti-inflammatory, antipeptic, antispasmodic, and antibacterial effects. It was investigated with encouraging results as an emulsion therapy for CT-induced mucositis ([@B122]--[@B126]). Studies are needed for its application in RIOM to determine its efficacy.

    10. Honey has been investigated in many preclinical studies due to its mucosal protective effect that was confirmed as a reduction in the incidence and severity of RIOM ([@B127]--[@B132]). However, the available clinical trial used only Manuka honey, and it appears to contradict the preclinical studies' results ([@B133]). More studies are needed to confirm the therapeutic potential of honey in RIOM.

    11. Sucralfate is a basic aluminum salt of sucrose sulfate that was used as mouthwash to reduce the intensity of RIOM and CCRT-induced mucositis as well ([@B39], [@B100], [@B134]--[@B151]). Despite its long application history, it is considered to have little effect in RIOM when compared to oral hygiene and symptomatic mucositis therapy ([@B2]). MASCC/ISOO Mucositis Guidelines did not find enough evidence for the beneficial application of sucralfate in OM ([@B34]).

    12. Vitamin A and its derivatives have anti-inflammatory and epithelial proliferative effect ([@B152]). Topical tretinoin has been shown to reduce the oral complications during bone marrow (BM) transplantation ([@B153]).

    13. Vitamin-E (tocopherol) has been shown to lower the oxidative damage of the oral mucosa and reduce the incidence of symptomatic RIOM in head and neck cancer patients in a randomized double-blind clinical trial ([@B152], [@B154]).

    14. Sodium alginate was shown to reduce the discomfort and the severity of RIOM in a randomized clinical trial ([@B155]).

    15. Benzydamine hydrochloride is a non-steroidal antimicrobial, anti-inflammatory, anesthetic, and analgesic agent that reduces pro-inflammatory cytokine production, scavenges the ROS, and acts as membrane stabilization and as an antimicrobial agent ([@B118], [@B156], [@B157]). When compared with chlorhexidine, patients with RIOM treated with benzydamine hydrochloride found more discomfort ([@B118]). Benzydamine hydrochloride failed to be approved by the US-FDA for OM management. Because of a negative interim analysis, a recent phase III trial for benzydamine hydrochloride therapy in RIOM was stopped ([@B33]).

    16. Povidone-iodine is an antiviral, antibacterial, and antifungal agent. Randomized clinical study showed that povidone-iodine reduces the incidence, severity, and duration of CCRT-induced OM, in addition to its advantages of being cheap and easily applied ([@B118], [@B158]--[@B160]).

    17. Capsaicin is an inhibitor of neutrophils that reduces the pain sensation. One clinical trial showed that orally applied capsaicin caused temporary relief of pain in mucositis caused by RT and CT ([@B161]). However, more studies are needed for optimization of its analgesic effect.

II. Systemically applied agents

    1.  Cyclooxegenase-2 inhibitors that have different mechanisms of action were applied in the management of RIOM. They suppress NF-κB, reduce pro-inflammatory-cytokine production, and inhibit angiogenesis ([@B162]--[@B164]). A randomized placebo-controlled trial showed that prophylactic systemic administration of indomethacin, a COX-2 inhibitor, significantly lowered the severity and delayed the onset of RIOM ([@B165]). In addition, PG E1 and E2 showed improvement in OM induced by RT and CT in few studies; however, their application is still controversial ([@B166]--[@B172]).

    2.  *N*-acetylcysteine is an antioxidant that has been shown to suppress NF-κB activation ([@B173], [@B174]). Because of its proven radioprotective role in RT-induced dermatitis, bone injury, liver toxicity, and intestinal injury ([@B173]--[@B188]), *N*-acetylcysteine was recommended as a candidate for a trial in RIOM. In a placebo-controlled phase II trial of patients with head and neck cancer, *N*-acetylcysteine significantly reduced the severity of RIOM ([@B33]).

    3.  Colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (GM-CSF) systemic therapy recruit neutrophils to the tissue injury site ([@B189]). Local application of GM-CSF mouthwash was shown marked alleviation of RIOM in several studies ([@B2]). Nevertheless, in clinical trials, its systemic application therapeutic value appears controversial ([@B190], [@B191]). SC GM-CSF reduced the severity of OM in patients treated with accelerated RT ([@B192]). In another randomized clinical study, systemic GM-CSF reduced the incidence of RIOM; however, another study did not show the same result ([@B140], [@B193]). Systemic GM-CSF therapeutic potential is still controversial and requires further investigation.

    4.  Transforming growth factor-β3 inhibits the oral basal cell proliferation. It was shown to reduce the incidence of CT-induced mucositis ([@B194]). However, a reliable clinical trial is needed to assess its therapeutic potential with RT.

    5.  Beta-carotene's antioxidative effect ([@B195], [@B196]) was implemented in a randomized clinical trial where there was a significant reduction in the incidence of severe OM in CCRT ([@B197]).

    6.  Analgesics are strong candidates for alleviating the pain related to RIOM. A retrospective study showed that opioid therapy remains a corner stone for OM pain management in CCRT, as suggested by the MASCC/ISOO guidelines ([@B33], [@B198]).

    7.  Azelastine is a potent second-generation selective histamine antagonist that is used as an anti-inflammatory and antioxidant agent. One clinical trial showed significant reduction in the incidence and the severity of OM with CCRT ([@B199]).

    8.  Propantheline is an anticholinergic agent that reduces the salivary flow. One clinical trial showed that propantheline and oral cryotherapy may be feasible and effective in reducing mucosal toxicity in cancer patients receiving high-dose CT ([@B200]). However, studies are needed for RIOM.

    9.  Immunoglobulins have lower salivary and systemic levels in patient receiving antineoplastic therapy. They have immune-modulating and anti-inflammatory properties. Intravenous or intramuscular immunoglobulins are frequently applied as prophylactic and therapeutic options for RIOM ([@B158], [@B201]).

    10. Systemic corticosteroids were used in RIOM management. A double-blind placebo-controlled randomized trial has shown a tendency toward reduced RT interruption in prednisone-treated relative to placebo-treated patient groups without evidence of reduced RIOM incidence or severity ([@B202]).

    11. Pentoxifylline regulates endotoxin-induced production of TNF-α. Although the preclinical studies showed significant reduction in the severity of RIOM with pentoxifylline ([@B203]), the clinical trials show that it is not effective in reducing the antineoplastic oral toxicity ([@B204]--[@B208]).

    12. Salicylic acid derivatives should be avoided due to the increased risk for bleeding ([@B34]--[@B36]).

    13. Sphingomyelinase and ceramide synthase inhibitors can be a potential candidate for RIOM. They inhibit the ceramide pathway-mediated RT-induced apoptosis ([@B209]--[@B216]). No current clinical trials have been started for them yet.

III. Oral microbial load reduction agents

     1.  Antimicrobial agents showed beneficial effect in prophylaxis and reduction of the severity of RIOM. RT injury leads to a change in the mucosal membrane barrier, salivary flow, and composition which favor the growth and colonization of different bacterial species, mainly Gram-negative bacteria. Many preclinical studies have investigated the therapeutic effect of different antimicrobial agents in RIOM ([@B217]--[@B220]). The FDA has granted fast track designation for brilacidin-OM, an oral rinse formulation of defensin-mimetic brilacidin ([@B221]--[@B223]), for the prevention of OM. There is a current phase II clinical trial to evaluate the safety and efficacy of brilacidin oral rinse in patients with head and neck cancer (NCT02324335).

     2.  Fungal infections are not involved directly in the development in RIOM, rather they can complicate the situation, especially in immunocompromised patients, and that is why the use of antifungal agents have been applied in RIOM treatment. A clinical study has shown that systemic fluconazole prophylaxis caused a significant beneficial effect on the severity of OM and on radiotherapy interruptions ([@B224]). The same effect was noted in randomized clinical trials investigating clotrimazole ([@B2]). Some oral mouthwashes containing amphotericin B have shown similar effects; however, due to carrier allergy, there might be a limitation in its application ([@B225]).

     3.  Antibacterial agents have been investigated in mucositis depending on a hypothesis stating that aerobic species (e.g., *Pseudomonas* spp. and *Staphylococcus epidermidis*), anaerobic bacteria (e.g., *Bacteroides* spp., and *Veillonella* spp.), and endotoxin of aerobic Gram-negative bacilli are considered a main contributor in the development of the secondary infection phase in RIOM ([@B2], [@B226]). Antibiotic lozenges with polymyxin-E and tobramycin have protected against severe mucositis when compared to placebo or chlorhexidine ([@B227]). In addition, ciprofloxacin- and ampicillin-containing mouthwashes showed similar effect ([@B228], [@B229]).

     4.  Antiviral agents against herpes simplex virus (HSV) type I and varicella zoster virus (VZV) were applied topically and systematically. HSV and VZV are the most common viral infections that aggravate RIOM in seropositive and myelo-suppressed patients ([@B230]--[@B232]). Systemic and topical acyclovir was investigated and applied in RIOM management and caused a reduction in the oral herpetic infections without an evident prophylactic role against OM itself ([@B233]--[@B238]).

Cellular Therapies for RIOM {#S11}
===========================

Bone marrow-derived mesenchymal stromal cells (bmMSCs) therapy have been applied in fractionated radiation-induced OM where the administration of a systemic single dose of six million MSCs resulted in a significant decrease in ED~50~ (the RT dose that produces ulcer in 50% of irradiated mice) ([@B239]). The first MSCs therapy for RIOM was done in 2014 by Schmidt et al. ([@B239]). They concluded that transplantation of BM or bmMSCs could modulate RIOM in fractionated RT, depending on the time of transplantation ([@B239]). Nevertheless, in another study, the authors concluded that bmMSCs transplantation had no therapeutic benefits on RIOM in single-dose RT when compared to the therapeutic effect of mobilization of endogenous BM stem cells ([@B240]). More studies are needed in this field building on the initial studies, which showed significant and clinically relevant therapeutic gain of MSCs therapy for RIOM (Table [10](#T10){ref-type="table"}).

###### 

**Radiation-induced oral mucositis (RIOM) the clinical trials that have been done until 2001 ([@B2])[^a^](#tfn2){ref-type="table-fn"}**.

  Injury       Reference                       Randomized/controlled/double blind   P/T     Application/doses                                                                     Results
  ------------ ------------------------------- ------------------------------------ ------- ------------------------------------------------------------------------------------- ----------------------------------------------------------------------
  RT           Shieh et al. ([@B241])          Yes/yes/no                           P       Instructions on oral care                                                             Significant reduction
                                                                                                                                                                                  
  RT           Perch et al. ([@B68])           No/no/no                             P       Midline mucosa-sparing blocks                                                         Decreased mucositis without affecting tumor control
                                                                                                                                                                                  
  RT           Rugg et al. ([@B242])           No/no/no                             P       Smoking during RT                                                                     Higher mucositis incidence in smokers
                                                                                                                                                                                  
  RT           Scherlacher et al. ([@B243])    Yes/yes/no                           P       Sucralfate vs. standard oral hygiene                                                  Significant reduction of incidence and severity of mucositis
                                                                                                                                                                                  
  RT           Allison et al. ([@B146])        Yes/yes/no                           P + T   Sucralfate + fluconazole vs. standard oral care                                       Significant reduced severity and symptomatic relief
                                                                                                                                                                                  
  RT           Franzen et al. ([@B145])        Yes/yes/yes                          P       Sucralfate vs. placebo                                                                Significant lower incidence of severe mucositis
                                                                                                                                                                                  
  RT           Makkonen et al. ([@B147])       Yes/yes/yes                          P       Sucralfate vs. placebo                                                                Only slight protective effect of sucralfate
                                                                                                                                                                                  
  RT           Epstein et al. ([@B148])        Yes/yes/yes                          P + T   Sucralfate vs. placebo                                                                Non-significant reduction of oral discomfort
                                                                                                                                                                                  
  RT           Meredith et al. ([@B144])       Yes/yes/yes                          T       Antacid, diphenhydramine, lidocaine ± sucralfate                                      Non-significant reduction of severity
                                                                                                                                                                                  
  RT           Cengiz et al. ([@B142])         Yes/yes/yes                          P + T   Sucralfate vs. placebo                                                                Decreased severity
                                                                                                                                                                                  
  RT           Carter et al. ([@B244])         Yes/yes/yes                          P       Sucralfate vs. placebo                                                                No difference
                                                                                                                                                                                  
  RT           Barker et al. ([@B100])         Yes/yes/yes                          P + T   Oral hygiene + sucralfate vs. diphenhydramine + kaolin-pectin                         No difference
                                                                                                                                                                                  
  RT           Feber et al. ([@B245])          Yes/yes/no                           P       Hydrogen peroxide vs. saline                                                          Significantly more oral discomfort
                                                                                                                                                                                  
  RT           Spijkervet et al. ([@B246])     Yes/yes/yes                          P + T   Chlorhexidine vs. placebo                                                             No difference
                                                                                                                                                                                  
  RT           Foote et al. ([@B117])          Yes/yes/yes                          P + T   Chlorhexidine vs. placebo                                                             Slight aggravation
                                                                                                                                                                                  
  HD-CT + RT   Ferretti et al. ([@B247])       Yes/yes/yes                          P + T   Chlorhexidine vs. placebo                                                             Significant reduction of incidence and severity in the CT group only
                                                                                                                                                                                  
  CT + RT      Rahn et al. ([@B157])           Yes/yes/no                           P       Nystatin, rutosides, immuno-globuines, panthenol ± PVP-iodine                         Significant reduction
                                                                                                                                                                                  
  CT + RT      Adamietz et al. ([@B159])       Yes/yes/no                           P       Nystatin, rutosides, immuno-globulines, panthenol ± PVP-iodine                        Significant reduction
                                                                                                                                                                                  
  CT + RT      Hasenau et al. ([@B248])        No/yes/no                            P       Hydrogen peroxide, PVP-iodine, dexpanthenol, nystatin                                 Lower incidence and severity of oral mucositis
                                                                                                                                                                                  
  RT           Spijkervet et al. ([@B227])     No/yes/no                            P       Lozenges of polymyxin, tobramycin, amphotericin vs. historical controls               Lower incidence of mucositis
                                                                                                                                                                                  
  RT           Mattews et al. ([@B228])        Yes/yes/no                           P       Sucralfate + (ciprofloxacin or ampicillin) + clotrimazole vs. sucralfate              Significant reduction of incidence and severity
                                                                                                                                                                                  
  RT           Symonds et al. ([@B249])        Yes/yes/yes                          P       Pastilles containing polymyxin, tobramycin, amphothericin vs. placebo                 Significant reduction of severe mucositis
                                                                                                                                                                                  
  RT           Okuno et al. ([@B250])          Yes/yes/yes                          P + T   Lozenges of polymyxin, tobramycin, amphotericin vs. placebo                           Significant reduction of oral discomfort, no objective difference
                                                                                                                                                                                  
  RT           Okuno et al. ([@B250])          Yes/yes/no                           T       Amphotericin + colistin + tobramycin + chlorhexidine vs. placebo                      Decreased oral discomfort
                                                                                                                                                                                  
  RT           Symonds et al. ([@B249])        Yes/yes/yes                          P       Amphotericin + tobramycin + polymyxin vs. placebo                                     Significant reduction of the incidence of sever mucositis
                                                                                                                                                                                  
  RT           Spijkervet et al. ([@B227])     No/yes/no                            P       Amphotericin + tobramycin + polymyxin vs. historical chlorhexidine or placebo group   Significant reduction of severity of mucositis
                                                                                                                                                                                  
  RT           Carl et al. ([@B251])           No/yes/no                            P + T   Chamomile vs. historical group                                                        Low incidence of mucositis
                                                                                                                                                                                  
  RT           Fidler et al. ([@B126])         Yes/yes/yes                          P       Chamomile vs. placebo, cryoprophylaxis in all patients                                No difference
                                                                                                                                                                                  
  RT           Abdelaal et al. ([@B252])       No/no/no                             P       High-dose betamethasone                                                               Impressive prevention of mucositis incidence
                                                                                                                                                                                  
  RT           Kim et al. ([@B253])            Yes/yes/yes                          P + T   Benzydamine vs. placebo                                                               Significant reduction (less pain)
                                                                                                                                                                                  
  RT           Epstein et al. ([@B156])        Yes/yes/yes                          P + T   Benzydamine vs. placebo                                                               Significant reduction of incidence and severity
                                                                                                                                                                                  
  RT           Samaranayake et al. ([@B254])   Yes/no/no                            P       Benzydamine vs. chlorhexidine                                                         No difference (more discomfort)
                                                                                                                                                                                  
  CT + RT      Prada et al. ([@B255])          Yes/yes/yes                          P + T   Benzydamine vs. placebo                                                               Significant reduction
                                                                                                                                                                                  
  RT           Huang et al. ([@B73])           Yes/yes/yes                          P       Parenteral glutamine vs. placebo                                                      No difference
                                                                                                                                                                                  
  CT + RT      Porteder et al. ([@B256])       No/yes/no                            P       PGE2 or nothing                                                                       Significant reduction (less pain)
                                                                                                                                                                                  
  RT           Matejka et al. ([@B171])        No/yes/no                            T       PGE2 tablets four times a day                                                         Reduction of mucositis severity
                                                                                                                                                                                  
  CT + RT      Hasenau et al. ([@B248])        No/no/no                             P + T   P + T hydrogen peroxide, nystatin                                                     Lower incidence of mucositis
                                                                                                                                                                                  
  RT           Rothwell et al. ([@B109])       Yes/yes/yes                          P       Hydrocortisone, nystatin, tetracyclines, diphenhydramine vs. placebo                  Significant reduction of incidence
                                                                                                                                                                                  
  RT           Maciejewski et al. ([@B257])    No/yes/no                            P       Applied to one side of buccal mucosa                                                  Significant reduction compared with contralateral side
                                                                                                                                                                                  
  RT           Barker et al. ([@B100])         Yes/yes/yes                                  Oral hygiene + sucralfate vs. diphenhydramine + kaolin-pectin                         No difference
                                                                                                                                                                                  
  CT + RT      Berger et al. ([@B161])         No/yes/no                            T       Capsaicin in a candy vehicle                                                          Significant temporary pain relief
                                                                                                                                                                                  
  CT + RT      Mills ([@B197])                 Yes/yes/no                           P       Beta-carotene or nothing                                                              Decreased severity in the treatment group
                                                                                                                                                                                  
  RT           Bourhis et al. ([@B258])        Yes/yes/no                           P       Amifostine or nothing                                                                 Marked reduction of mucositis (tolerance was poor)
                                                                                                                                                                                  
  RT           Koukourakis et al. ([@B259])    Yes/yes/yes                          P       Amifostine vs. saline                                                                 Significant reduction of mucositis
                                                                                                                                                                                  
  RT           Schonekas et al. ([@B260])      No/yes/no                            P       Amifostine vs. controls                                                               Significant reduction of mucositis
                                                                                                                                                                                  
  RT           Wagner et al. ([@B261])         Yes/yes/no                           P       Amifostine or nothing                                                                 Significant reduction of mucositis
                                                                                                                                                                                  
  CT + RT      Buntzel et al. ([@B262])        Yes/yes/no                           P       Amifostine or nothing                                                                 Significant reduction of mucositis and xerostomia
                                                                                                                                                                                  
  CT + RT      Peters et al. ([@B263])         Yes/yes/no                           P       Amifostine or nothing                                                                 No significant difference
                                                                                                                                                                                  
  CT + RT      Vacha et al. ([@B264])          Yes/yes/no                           P       Amifostine or nothing                                                                 Trend toward reduction of mucositis
                                                                                                                                                                                  
  CT + RT      Osaki et al. ([@B199])          Yes/yes/no                           P       Vitamins C + E, glutathione ± azelastine                                              Significant reduction
                                                                                                                                                                                  
  RT           Pillsbury et al. ([@B165])      Yes/yes/yes                          P       Indomethacin vs. placebo                                                              Significant delay of mucositis onset
                                                                                                                                                                                  
  CT + RT      Mose et al. ([@B201])           No/yes/no                            P       i.m. immunoglobulins                                                                  Significant reduction in CT + RT patients, no difference in RT
                                                                                                                                                                                  
  RT           Wagner et al. ([@B265])         Yes/yes/no                           P       RT + GM-CSF vs. historical control                                                    Significant lower severity of mucositis
                                                                                                                                                                                  
  RT           Makkonen et al. ([@B140])       No/yes/no                            P       Sucralfate ± GM-CSF                                                                   No difference
                                                                                                                                                                                  
  RT           Kannan et al. ([@B193])         No/yes/no                            P       RT + GM-CSF                                                                           Lower incidence of severe mucositis
                                                                                                                                                                                  
  CT + RT      Rosso et al. ([@B266])          No/yes/no                            P       GM-CSF vs. historical control sig. lower incidence of severe mucositis                Lower incidence of severe mucositis
                                                                                                                                                                                  
  RT           Mascarin et al. ([@B267])       Yes/yes/no                           P       RT ± G-CSF                                                                            Less treatment interruptions only
                                                                                                                                                                                  
  RT           Schneider et al. ([@B268])      Yes/yes/yes                          P       RT ± G-CSF                                                                            Significant reduced incidence of severe mucositis
                                                                                                                                                                                  
  CT + RT      Bubley et al. ([@B236])         Yes/yes/yes                          P       Acyclovir vs. placebo                                                                 No impact upon incidence and severity of mucositis

*RT, radiotherapy; P/T, prevention or treatment; CT, chemotherapy; HD-CT, high-dose chemotherapy; BMT, bone marrow transplantation; TBI, total body irradiation; i.m., intramuscular; G-CSF, colony-stimulating factor; GM-CSF, granulocyte-macrophage colony-stimulating factor*.

*^a^Published with permission from Dr. Christoph C. Zielinski*.

Clinical Trials for RIOM {#S11-1}
------------------------

Table [10](#T10){ref-type="table"} summarizes the clinical trials that were done until 2001 for prevention (P) and treatment (T) of RIOM ([@B2]). The current clinical trials for RIOM are summarized in Table [11](#T11){ref-type="table"} and were found when searching the clinical trials website of the National Institute of Health for RIOM. We have documented 40 RIOM treatment and prevention clinical trials.

###### 

**Clinical trials for RIOM as listed on *<http://www.ClinicalTrials.gov>* when searched in November 2015**.

  NCT number    Title                                                                                                                                                                                            Conditions                                                                                                                                                                                                                   Last updated
  ------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------
  NCT02508389   A Study of GC4419 Protection against Radiation Induced Oral Mucositis in Patients with Head & Neck Cancer                                                                                        Radiation-Induced Oral Mucositis                                                                                                                                                                                             23 November 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00698204   Cox-2 Inhibition in Radiation-Induced Oral Mucositis                                                                                                                                             Oral Mucositis                                                                                                                                                                                                               7 May 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00814359   Magic Mouthwash Plus Sucralfate Versus Benzydamine Hydrochloride for the Treatment of Radiation-Induced Mucositis                                                                                Head and Neck Cancer\|Mucositis                                                                                                                                                                                              19 January 2011
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01400620   Safety and Efficacy of IZN-6N4 Oral Rinse for the Prevention of Oral Mucositis in Patients with Head and Neck Cancer                                                                             Oral Mucositis                                                                                                                                                                                                               9 November 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00051441   Safety & Efficacy Study of Benzydamine Oral Rinse for the Treatment of Oral Mucositis (Mouth Sores) Resulting From Radiation Therapy for Cancer of the Oral Cavity, Oropharynx, or Nasopharynx   Stomatitis\|Radiation Effects                                                                                                                                                                                                17 May 2011
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02608879   Oral Care Protocol for the Management of Chemotherapy and Radiation Therapy-Induced Oral Mucositis                                                                                               Oral Mucositis\|Oral Cancer                                                                                                                                                                                                  17 November 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01465308   The Effect of Honey on Xerostomia and Oral Mucositis                                                                                                                                             Head and Neck Cancer                                                                                                                                                                                                         7 October 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01375088   Assessing the Preventing and Therapeutic Effect of Propolis in Radiotherapy Induced Mucositis of Head and Neck Cancers                                                                           Radiation-induced Mucositis of Oral Mucous Membranes                                                                                                                                                                         21 November 2012
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01066741   Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer                                                                                  Oropharynx Cancer\|Hypopharynx Cancer                                                                                                                                                                                        31 October 2012
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00006994   S9908: Glutamine in Treating Mucositis Caused by Radiation Therapy in Patients with Newly Diagnosed Cancer of the Mouth or Throat                                                                Cancer-related Problem/Condition\|Head and Neck Cancer\|Pain                                                                                                                                                                 17 November 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02430298   Topical/Oral Melatonin for Preventing Concurrent Radiochemotherapy Induced Oral Mucositis/Xerostomia Cancer Patients                                                                             Head and Neck Cancer                                                                                                                                                                                                         12 May 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02397486   The Impact of Pentoxifylline and Vitamin E on Radiotherapy-induced Toxicity in Head & Neck Cancer Patients                                                                                       Head and Neck Neoplasms                                                                                                                                                                                                      27 May 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01941992   Role of SAMITAL^®^ in the Relief of Chemoradiation (CT-RT) Induced Oral Mucositis in Head and Neck Cancer Patients                                                                               Head-and-neck Squamous Cell Carcinoma\|Oral Mucositis                                                                                                                                                                        24 March 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01318889   Dexpanthenol Mouthwash to Treat Oral Mucositis                                                                                                                                                   Oral Mucositis (Ulcerative) Due to Radiation                                                                                                                                                                                 5 July 2011
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02016807   ZeroTolerance Mucositis: Managing Oral and Alimentary Mucositis with High Potency Sucralfate---ProThelial                                                                                        Oral Mucositis\|Nausea\|Vomiting\|Diarrhea                                                                                                                                                                                   16 December 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00293462   GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer                                                                 Head and Neck Cancer\|Mucositis\|Radiation Toxicity                                                                                                                                                                          14 May 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00728585   Palifermin in Preventing Oral Mucositis Caused by Chemotherapy and/or Radiation Therapy in Young Patients Undergoing Stem Cell Transplant                                                        Breast Cancer\|Graft vs. Host Disease\|Kidney Cancer\|Leukemia\|Lymphoma\|Mucositis\|Multiple Myeloma\|Plasma Cell Neoplasm\|Myelodysplastic Syndromes\|Neuroblastoma\|Ovarian Cancer\|Sarcoma\|Testicular Germ Cell Tumor   30 May 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02604329   Feasibility Study of a Protocol to Treat Pediatric Oral Mucositis by Low-Level Laser Therapy                                                                                                     Oral Mucositis                                                                                                                                                                                                               12 November 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02075749   Comparing Triamcinolone Acetonide Mucoadhesive Films with Licorice Mucoadhesive Films                                                                                                            Mucositis                                                                                                                                                                                                                    9 July 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01385748   Efficacy and Safety Study of Clonidine Lauriad^®^ to Treat Oral Mucositis                                                                                                                        Oral Mucositis                                                                                                                                                                                                               7 July 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01707641   Effect of Lactobacillus Brevis CD2 in Prevention of Radio-chemotherapy Induced Oral Mucositis in Head and Neck Cancer                                                                            Mucositis                                                                                                                                                                                                                    19 May 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00613743   Effect of Topical Morphine (Mouthwash) on Oral Pain Due to Chemo- and/or Radiotherapy Induced Mucositis                                                                                          Cancer\|Mucositis                                                                                                                                                                                                            12 January 2010
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00431925   Can Cytokines Predict the Severity of Acute Mucositis and the Need for Gastrostomy Tubes (PEG)?                                                                                                  Oral Mucositis\|Xerostomia\|Weight Loss\|Head and Neck Cancer                                                                                                                                                                9 August 2007
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01806272   Recombinant Human Granulocyte Macrophage Colony-Stimulating Factor (rhGM-CSF) Treating Oral Mucositis                                                                                            Nasopharyngeal Cancers                                                                                                                                                                                                       27 March 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01876407   Effectiveness of Low Energy Laser Treatment in Oral Mucositis Induced by Chemotherapy and Radiotherapy in Head and Neck Cancer                                                                   Oral Mucositis                                                                                                                                                                                                               30 April 15
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00584597   A Trial of Homeopathic Medication TRAUMEEL S for the Treatment of Radiation-Induced Mucositis                                                                                                    Mucositis\|Head and Neck Cancer                                                                                                                                                                                              10 December 2010
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00615420   A Randomized Placebo-Controlled Trial of Manuka Honey for Oral Mucositis Due to Radiation Therapy for Cancer                                                                                     Radiotherapy-Induced Mucositis\|Head and Neck Cancer                                                                                                                                                                         22 May 2012
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01898091   Herbal Mouthrinse for Oral Mucositis Study                                                                                                                                                       Oral Mucositis                                                                                                                                                                                                               2 1 Septmebr 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01772706   Laser Mucite ORL: Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer                                                                           Oral Squamous Cell Carcinoma\|Squamous Cell Carcinoma of Oropharynx\|Squamous Cell Carcinoma of Hypopharynx\|Oral Mucositis                                                                                                  17 January 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01837446   Morphine Mouthwash for Management of Oral Mucositis in Patients with Head and Neck Cancer                                                                                                        Stomatitis                                                                                                                                                                                                                   22 April 2013
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02309437   Early Use of Opioid to Control Local Mucosa Pain Induced by Irradiation in Nasopharyngeal Carcinoma Patients                                                                                     Nutrition Disorders\|Quality of Life                                                                                                                                                                                         3 December 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01668849   Edible Plant Exosome Ability to Prevent Oral Mucositis Associated with Chemoradiation Treatment of Head and Neck Cancer                                                                          Head and Neck Cancer\|Oral Mucositis                                                                                                                                                                                         12 May 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01975688   A Pharmacokinetic Study of Single Doses of Sativex in Treatment-Induced Mucositis                                                                                                                Head and Neck Squamous Cell Carcinoma                                                                                                                                                                                        12 May 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01252498   Evaluation of the Role of Prostaglandins in Radiation-induced Mucositis                                                                                                                          Cancer of the Head and Neck\|Radiotherapy                                                                                                                                                                                    3 February 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01840436   Efficacy of MUCIPLIQ on the Incidence of Radio-chemotherapy-Induced Mucositis in Patients Suffering From Oral Cancer                                                                             Oral Mucositis\|Carcinoma *in Situ* of Upper Respiratory Tract                                                                                                                                                               15 May 2014
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT00699569   Hyperimmune Colostrum and Oral Mucositis                                                                                                                                                         Head and Neck Cancer                                                                                                                                                                                                         22 July 2008
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02555501   Oral Mucositis and Laser Therapy Associated with Photodynamic Therapy                                                                                                                            Oral Mucositis                                                                                                                                                                                                               18 September 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT02050503   Intranasal Transmucosal Fentanyl Pectin for Breakthrough Cancer Pain in Radiation-Induced Oropharyngeal Mucositis                                                                                Breakthrough Pain\|Mucositis\|Radiotherapy\|Chemotherapy\|Head and Neck Cancer                                                                                                                                               16 March 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01883908   Acupuncture in Reducing the Severity of Chemoradiation-Induced Mucositis in Patients with Oropharyngeal Cancer                                                                                   Mucositis\|Oropharyngeal Cancer                                                                                                                                                                                              3 September 2015
                                                                                                                                                                                                                                                                                                                                                                                                                                              
  NCT01432873   Oral Selenium Therapy for the Prevention of Mucositis                                                                                                                                            Mucositis\|Hematopoietic Stem Cell transplantation                                                                                                                                                                           31 May 2012

Conclusion {#S12}
==========

Despite its high incidence, RIOM is a self-limited radiotherapy-induced normal tissue injury. It is a dose-limiting toxicity in most cases of head and neck cancer patients. However, in moderately to severely sick patients, it could be a lethal injury. Many preclinical and clinical studies have been conducted for the prevention and treatment of RIOM. Currently, there are numerous prevention and treatment strategies for RIOM. However, there is no single agent or management regimen that has been agreed upon between caregivers that significantly improves RIOM to a clinically relevant and satisfactory standard. Nevertheless, the current guidelines recommend good oral care, IMRT, radiation shields, palifermin, amifostine, and cryotherapy for RIOM prevention. RIOM treatment focuses on palliative measures and symptoms relief; e.g., pain management, nutritional support, good oral hygiene, and reduced oral microbial load. Interestingly, mesenchymal stromal cells therapy for RIOM shows promise for potential therapeutic and clinically relevant benefits. However, more studies are still needed to confirm such therapeutic potential.
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